These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 38756783)

  • 1. Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination.
    Hyun H; Nham E; Seong H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SK; Park SJ; Gwak W; Lee JW; Kim B; Song JY
    Front Immunol; 2024; 15():1385135. PubMed ID: 38756783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
    Kawashiro K; Suzuki R; Nogimori T; Tsujino S; Iwahara N; Hirose T; Okada K; Yamamoto T; Fukuhara T; Hotta K; Shinohara N
    Sci Rep; 2024 May; 14(1):12176. PubMed ID: 38806644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.
    Li H; Yang C; Yin L; Liu W; Zhang Z; Liu B; Sun X; Liu W; Lin Z; Liu Z; He P; Feng Y; Wang C; Wang W; Guan S; Wang Q; Chen L; Li P
    Emerg Microbes Infect; 2024 Dec; 13(1):2387447. PubMed ID: 39082740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of cross-neutralizing immunity following COVID-19 primary series vaccination during the Omicron surge in Tanzania.
    Nkinda L; Barabona G; Ngare I; Nkuwi E; Kamori D; Msafiri F; Kunambi PP; Osati E; Kidenya BR; Chuwa H; Kinasa G; Hassan FE; Judicate GP; Gasper J; Kisuse J; Mfinanga S; Senkoro M; Ueno T; Lyamuya E; Balandya E
    J Med Virol; 2024 Aug; 96(8):e29822. PubMed ID: 39056238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters.
    Zhang XS; Windau A; Meyers J; Yang X; Dong F
    Microbiol Spectr; 2024 Oct; 12(10):e0060524. PubMed ID: 39162540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants.
    Fryer HA; Geers D; Gommers L; Zaeck LM; Tan NH; Jones-Freeman B; Goorhuis A; Postma DF; Visser LG; Hogarth PM; Koopmans MPG; GeurtsvanKessel CH; O'Hehir RE; van der Kuy PHM; de Vries RD; van Zelm MC
    J Infect; 2024 Oct; 89(4):106246. PubMed ID: 39127451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations.
    Song XD; Yang GJ; Shi C; Jiang XL; Wang XJ; Zhang YW; Wu J; Zhao LX; Wang MM; Chen RR; He XJ; Dai EH; Shen Y; Gao HX; Dong G; Ma MJ
    Int J Infect Dis; 2024 Oct; 147():107198. PubMed ID: 39117174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
    Chalkias S; McGhee N; Whatley JL; Essink B; Brosz A; Tomassini JE; Girard B; Edwards DK; Wu K; Nasir A; Lee D; Avena LE; Feng J; Deng W; Montefiori DC; Baden LR; Miller JM; Das R
    J Infect Dis; 2024 Aug; 230(2):e279-e286. PubMed ID: 38349280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID-19 Booster Vaccines and Recent SARS-CoV-2 Omicron Variant Infections.
    Jeong HW; Rollon R; Kim SM; Gil J; Casel MA; Jang H; Choi JH; Jang SG; Lazarte JC; Kim HS; Kim JH; Choi YK
    Influenza Other Respir Viruses; 2024 Oct; 18(10):e70000. PubMed ID: 39377176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
    Poh XY; Torres-Ruesta A; Yoong T; Wong N; Tan CW; Rouers A; Chavatte JM; Goh YS; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Neo V; Kam IKJ; Huang Y; Hor PX; Loh CY; ; Yeoh AY; Lim DRX; Chia W; Ren EC; Lin RTP; Fong SW; Renia L; Lye DC; Wang LF; Ng LFP; Young BE
    Vaccine; 2024 Nov; 42(25):126275. PubMed ID: 39241318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
    Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
    Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations.
    Hyun HJ; Choi MJ; Nham E; Seong H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SK; Park SJ; Gwak WS; Lee JW; Kim BG; Song JY
    Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific humoral immune response and XBB variants re-infection risk of hemodialysis patients after Omicron BA.5 infection in China.
    Mai W; Shen J; Ma F; Zhu J; Chen L; Lei Y; Yu P; Niu C; Wang F; Yan S; Mai X; He P; Liao L; Xiong X; Zheng Y; Liu Q; Huang Y; Wang Q; Liang J; Ji T
    Vaccine; 2024 Aug; 42(21):126108. PubMed ID: 39048466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.
    Lustig Y; Barda N; Weiss-Ottolenghi Y; Indenbaum V; Margalit I; Asraf K; Doolman R; Chalkias S; Das R; Elfatarany G; Harats D; Kreiss Y; Regev-Yochay G
    Vaccine; 2024 Sep; 42(22):126010. PubMed ID: 38806352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
    Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
    Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection.
    Jiang XL; Song XD; Shi C; Yang GJ; Wang XJ; Zhang YW; Wu J; Zhao LX; Zhang MZ; Wang MM; Chen RR; He XJ; Dai EH; Gao HX; Shen Y; Dong G; Wang YL; Ma MJ
    Cell Rep; 2024 Jul; 43(7):114387. PubMed ID: 38896777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.
    Muñoz-Gómez MJ; Ryan P; Quero-Delgado M; Martin-Vicente M; Cuevas G; Valencia J; Jiménez E; Blanca-López N; Lara-Álvarez MÁ; Hernández-Rivas JÁ; Redondo G; Mas V; Sepúlveda-Crespo D; Vázquez M; Torres-Macho J; Martínez I; Resino S
    J Infect Public Health; 2024 Jul; 17(7):102473. PubMed ID: 38865774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine.
    Nguyenla XH; Bates TA; Trank-Greene M; Wahedi M; Tafesse FG; Curlin ME
    Emerg Infect Dis; 2024 Jun; 30(6):1282-1283. PubMed ID: 38669121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.